公开(公告)号：US20200369761A1

公开(公告)日：2020-11-26

申请号：US16880118

申请日：2020-05-21

Applicant: Janssen Biotech, Inc.

Inventor： Mathew Germinaro ,  Christopher O'Brien ,  Jacqueline Perrigoue

IPC: C07K16/24 ,  A61K9/00 ,  A61P1/04 ,  A61P29/00

Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).

公开(公告)号：US20200095315A1

公开(公告)日：2020-03-26

申请号：US16580509

申请日：2019-09-24

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johans ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61K9/08 ,  A61K47/22 ,  A61K47/26 ,  A61K47/18 ,  A61K9/00 ,  A61P1/04

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20240182557A1

公开(公告)日：2024-06-06

申请号：US18383310

申请日：2023-10-24

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/08 ,  A61K39/00 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61K9/08 ,  A61K39/00 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/565

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20240010718A1

公开(公告)日：2024-01-11

申请号：US18327577

申请日：2023-06-01

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Christopher O'Brien ,  Jacqueline Perrigoue

IPC: C07K16/24 ,  A61K9/00 ,  A61P1/04 ,  A61P29/00 ,  A61K39/395

CPC classification number: C07K16/244 ,  C07K16/241 ,  A61K9/0019 ,  A61P1/04 ,  A61P29/00 ,  A61K39/395 ,  C07K2317/31 ,  C07K2317/565 ,  A61K2039/545

Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).